Klaus Urbahns

Fluctuating Open Teams(FLOT) - A New Approach to Boost Team Creativity and Innovation Potential

Ulrich A. K. Betz, Paul Czodrowski, Christina Esdar, 2014 .

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.

Julian Blagg, Djordje Musil, Paul Czodrowski, 2016, Journal of medicinal chemistry.

Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies

Klaus Urbahns, B. Huck, Bayard R Huck, 2018, Angewandte Chemie.

Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides.

Noriyuki Yamamoto, Takeshi Yura, Kentaro Hashimoto, 2005, Bioorganic & medicinal chemistry letters.

Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5-sulfonamides.

Noriyuki Yamamoto, Takeshi Yura, Kentaro Hashimoto, 2005, Bioorganic & medicinal chemistry letters.

Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites.

Didier Rognan, Chris de Graaf, Steve Price, 2009, Journal of medicinal chemistry.

Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.

Bo Nordén, Klaus Urbahns, B. Springthorpe, 2008, Journal of medicinal chemistry.

Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.

Noriyuki Yamamoto, Takeshi Yura, Klaus Urbahns, 2005, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.

Julian Blagg, Djordje Musil, Paul Czodrowski, 2016, Bioorganic & medicinal chemistry letters.